Market Overview

BioLineRx Presents Positive Preclinical Results of AML Treatment at ASH


BioLineRx (NASDAQ: BLRX) announced today that positive preclinical results of BL-8040 (formerly known as BKT-140), for the treatment of Acute Myeloid Leukemia (AML) and other hematological indications, have been presented as a poster at the 55th Annual Meeting of the American Society of Hematology (ASH). The data show that BL-8040 is efficient in inducing the death of AML cancer cells both in vitro and in a humanized mouse model. #ASH13

See full press release

Posted-In: News Guidance Management Global


Related Articles (BLRX)

View Comments and Join the Discussion!

Benzinga's Top Upgrades

Talisman Energy Announces $595M Sale of Colombian Ocensa Pipeline to Advent-Led Group